8-K: Qualigen Therapeutics Secures $4.5 Million in Private Placement of Series A-3 Preferred Stock

Qualigen Therapeutics, Inc. announced the closing of a private placement, raising approximately $4.5 million through the sale of Series A-3 Preferred Stock to fund working capital and investor relations.

Summary

• Qualigen Therapeutics, Inc. completed a private placement on July 28, 2025, issuing 4,500 shares of newly designated Series A-3 Preferred Stock at $1,000 per share.
• The transaction generated aggregate gross proceeds of approximately $4.5 million, with net proceeds intended for working capital and up to $500,000 for an investor relations agency.
• The Series A-3 Preferred Stock is convertible into 1,607,143 shares of common stock at an initial conversion price of $2.80 per share, which was the official closing price on July 25, 2025.
• The company is required to file a registration statement on Form S-1 for the resale of the underlying common stock within 45 days of the closing date.
• The issuance of Series A-3 Preferred Stock triggered an automatic anti-dilution adjustment for the outstanding Series A-2 Convertible Preferred Stock, reducing its conversion price from $3.64 to $2.80 per share, effective July 28, 2025.

Sentiment

Score: 6

Explanation: The capital raise provides necessary working capital for a clinical-stage biotech, which is positive for operations. However, the significant dilution potential from the preferred stock conversion and the anti-dilution trigger for existing preferred stock (Series A-2) at a lower price point introduce notable negative aspects and risks for common shareholders.

Positives

• Secured approximately $4.5 million in gross proceeds, providing capital for working capital purposes.
• Funds allocated for working capital and investor relations, supporting ongoing operations and market communication.
• The private placement was completed with institutional and accredited investors, indicating investor confidence.

Negatives

• The issuance of new preferred stock and potential conversion into common stock will result in dilution for existing common stockholders.
• The conversion price of $2.80 per share for the Series A-3 Preferred Stock is relatively low, potentially leading to significant dilution if converted.
• The anti-dilution provision for Series A-3 Preferred Stock, with a floor price of $1.40, could lead to further dilution if future equity is issued at lower prices.
• The anti-dilution trigger for Series A-2 Preferred Stock, reducing its conversion price from $3.64 to $2.80, indicates a lower valuation for previous preferred stock holders and potential for increased dilution from that series as well.

Risks

• Dilution Risk: Future conversion of Series A-3 Preferred Stock into common stock will increase the number of outstanding common shares, diluting the ownership percentage of existing common stockholders.
• Anti-Dilution Provisions: The Series A-3 Preferred Stock includes anti-dilution protection, which could further reduce the conversion price if the company issues common stock or equivalents at a lower effective price, potentially leading to greater dilution.
• Beneficial Ownership Limitations: Holders are limited to converting shares if it results in beneficial ownership exceeding 4.99% (or 9.99% with notice) of outstanding common stock, which could affect liquidity for large holders.
• Liquidation Preference: Series A-3 Preferred Stock is senior to common stock in liquidation, meaning common stockholders would be paid after Series A-3 holders in a liquidation event. It is junior to Series A-2 Preferred Stock.
• Negative Covenants: The company is restricted from certain corporate actions (e.g., amending charter adversely, repurchasing junior securities, paying cash dividends on junior securities, certain related-party transactions) without consent from 67% of Series A-3 holders, which could limit corporate flexibility.
• Market Price Volatility: The conversion price is tied to the common stock's closing price, and future price fluctuations could impact the value and conversion dynamics of the preferred stock.

Future Outlook

The company intends to use the net proceeds from the sale of the Series A-3 Preferred Stock for working capital purposes and has committed to filing a registration statement for the resale of the underlying common stock within 45 days of the closing date, indicating a plan for future liquidity for the investors.

Management Comments

• Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases.
• The Company's pipeline includes QN-302, a selective G-quadruplex inhibitor targeting various tumor types including pancreatic cancer; QN-247, a nucleolin-targeting compound for hematologic malignancies; and a family of small-molecule RAS oncogene protein-protein interaction inhibitors.
• Each of these programs is designed to address areas of high unmet medical need, with the potential for orphan drug designation.
• Qualigen is committed to advancing its therapeutic pipeline to improve patient outcomes and create long-term value for shareholders.

Industry Context

This capital raise provides Qualigen Therapeutics with additional working capital to advance its clinical-stage biotechnology pipeline, which focuses on novel therapeutics for cancer and infectious diseases. The company's focus on G-quadruplex inhibitors, nucleolin-targeting compounds, and RAS oncogene protein-protein interaction inhibitors positions it within the competitive and high-risk, high-reward oncology and infectious disease therapeutic development space. The pursuit of orphan drug designations suggests a strategy to target rare diseases, which can offer market exclusivity and other incentives.

Corporate Governance

Related Party Transactions

• The company is restricted from entering into certain related-party transactions unless on arms-length terms and approved by a majority of disinterested directors, without the prior written consent of holders of at least 67% of the outstanding Series A-3 Preferred Stock.

Stakeholder Impact

• Shareholders (Common Stock): Will experience dilution from the conversion of Series A-3 Preferred Stock and the anti-dilution adjustment to Series A-2 Preferred Stock, potentially impacting per-share value.
• Shareholders (Series A-2 Preferred Stock): Benefit from an anti-dilution adjustment, lowering their conversion price from $3.64 to $2.80, which could increase their potential common stock holdings upon conversion.
• Investors (Series A-3 Preferred Stock): Provide capital and receive preferred stock with conversion rights, anti-dilution protection, and liquidation preference senior to common stock, along with registration rights for resale.
• Company Operations: Receives working capital to fund ongoing operations and advance its therapeutic pipeline.

Next Steps

• File a registration statement on Form S-1 covering the resale of common stock underlying the Series A-3 Preferred Stock no later than 45 days following the closing date (by September 11, 2025).
• Use commercially reasonable efforts to cause the registration statement to be declared effective as soon as practicable thereafter.
• Advance the therapeutic pipeline, including QN-302, QN-247, and RAS oncogene protein-protein interaction inhibitors.
• Potentially pursue orphan drug designations for pipeline programs.

Key Dates

Recommendation

The capital raise provides essential working capital for Qualigen Therapeutics, a positive for a clinical-stage biotech. However, the significant potential for dilution from the Series A-3 Preferred Stock conversion, coupled with the anti-dilution adjustment impacting the Series A-2 Preferred Stock, creates downward pressure on the common stock. While the funding is crucial for operations, the dilutive nature of the financing and the implications for existing shareholders suggest a 'hold' position until there is clearer visibility on the company's clinical progress and how the market absorbs the increased share count.

Keywords

Qualigen Therapeutics, QLGN, Private Placement, Series A-3 Preferred Stock, Convertible Preferred Stock, Capital Raise, SEC Filing, 8-K, Dilution, Anti-Dilution, Working Capital, Biotechnology, Oncology, Nasdaq